facs buffer Search Results


bsa  (Rockland Immunochemicals)
95
Rockland Immunochemicals bsa
Bsa, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/facs+buffer/pmc10843729-127-15-18?v=Rockland+Immunochemicals
Average 95 stars, based on 1 article reviews
bsa - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier
facs buffer  (Rockland Immunochemicals)
93
Rockland Immunochemicals facs buffer
Facs Buffer, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/facs+buffer/med_rxiv__2025__11__18__25340499-316-4-6?v=Rockland+Immunochemicals
Average 93 stars, based on 1 article reviews
facs buffer - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
irdye blocking buffer  (Rockland Immunochemicals)
93
Rockland Immunochemicals irdye blocking buffer
Irdye Blocking Buffer, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/facs+buffer/pmc04666965-85-4-7?v=Rockland+Immunochemicals
Average 93 stars, based on 1 article reviews
irdye blocking buffer - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier
200 to 700 facs buffer  (Becton Dickinson)
90
Becton Dickinson 200 to 700 facs buffer
200 To 700 Facs Buffer, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/facs+buffer/us09453068-1019-12-22?v=Becton+Dickinson
Average 90 stars, based on 1 article reviews
200 to 700 facs buffer - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
facs buffer  (Becton Dickinson)
90
Becton Dickinson facs buffer
Facs Buffer, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/facs+buffer/pm25344321-74-6-13?v=Becton+Dickinson
Average 90 stars, based on 1 article reviews
facs buffer - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
flow cytometry buffer  (STEMCELL Technologies Inc)
90
STEMCELL Technologies Inc flow cytometry buffer
LipoTLR + I generate tolDCs that actively uptake antigen in vitro and in vivo. (A) Analysis of LipoTLR + I In Vitro. 100 k BMDCs were treated with free or liposomal formulations of TLR + I, TLR or I and analyzed via flow <t>cytometry</t> for liposomal uptake. Liposomes were synthesized with AF647-OVA for a total of 1 μg of OVA per .1 μM of inhibitor (using loading procedure from Figure S-4). Free inhibitor formulations were treated with equivalent OVA dose. 1 h after second treatment, cells were washed and analyzed via flow for OVA internalization (B) In Vivo Analysis of LipoTLR + I uptake. C57BL/6 mice (4 per group) were injected with either free or Lipo formulations of OVA and combinations of inhibitors to for the following categories (100 μg OVA/mouse, 10 umols inhibitor/mouse, 1 μg FLA/mouse, 10 μg CpG/mouse) [1]: OVA alone (PBS) [2], OVA + TLR agonists (TLR), OVA + TLR agonists + dexsamethasone only (TLR + Dex) or OVA + Inhibitor combination (TLR + I). For Lipo formulations, DiD was added at 0.01% total lipid loading to allow fluorescent analysis. Mice were injected with either Lipo or free combinations i.p. with FLA then CpG formulations on consecutive days. 24 h after final CpG injection, mice were sacrificed, popliteal and inguinal lymph nodes harvested, disassociated and stained for various immune cell markers. Lymph cells were analyzed via spectral flow and DC populations (CD45+, MHCII+, CD11c+, CD19−) analyzed for CD40, (C) CD80 (D) CD86 (E) CD103 (F) PD-L1 (G) PD-L2. (H) Mice treated with liposomes were gated on Liposome+ and PD-L1/2 + cell populations. Error bars indicate ± of SD of each mouse group (N = 4). Significance was determined by a two-way ANOVA with Tukey post hoc test for multiple comparisons. *p < 0.5, **p < 0.01, ***p < 1 × 10−4, ****p < 1 × 10−5..
Flow Cytometry Buffer, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/facs+buffer/pmc10152544-676-5-8?v=STEMCELL+Technologies+Inc
Average 90 stars, based on 1 article reviews
flow cytometry buffer - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
facs buffer (pbs edta lonza with 2% fcs)  (Lonza)
90
Lonza facs buffer (pbs edta lonza with 2% fcs)
LipoTLR + I generate tolDCs that actively uptake antigen in vitro and in vivo. (A) Analysis of LipoTLR + I In Vitro. 100 k BMDCs were treated with free or liposomal formulations of TLR + I, TLR or I and analyzed via flow <t>cytometry</t> for liposomal uptake. Liposomes were synthesized with AF647-OVA for a total of 1 μg of OVA per .1 μM of inhibitor (using loading procedure from Figure S-4). Free inhibitor formulations were treated with equivalent OVA dose. 1 h after second treatment, cells were washed and analyzed via flow for OVA internalization (B) In Vivo Analysis of LipoTLR + I uptake. C57BL/6 mice (4 per group) were injected with either free or Lipo formulations of OVA and combinations of inhibitors to for the following categories (100 μg OVA/mouse, 10 umols inhibitor/mouse, 1 μg FLA/mouse, 10 μg CpG/mouse) [1]: OVA alone (PBS) [2], OVA + TLR agonists (TLR), OVA + TLR agonists + dexsamethasone only (TLR + Dex) or OVA + Inhibitor combination (TLR + I). For Lipo formulations, DiD was added at 0.01% total lipid loading to allow fluorescent analysis. Mice were injected with either Lipo or free combinations i.p. with FLA then CpG formulations on consecutive days. 24 h after final CpG injection, mice were sacrificed, popliteal and inguinal lymph nodes harvested, disassociated and stained for various immune cell markers. Lymph cells were analyzed via spectral flow and DC populations (CD45+, MHCII+, CD11c+, CD19−) analyzed for CD40, (C) CD80 (D) CD86 (E) CD103 (F) PD-L1 (G) PD-L2. (H) Mice treated with liposomes were gated on Liposome+ and PD-L1/2 + cell populations. Error bars indicate ± of SD of each mouse group (N = 4). Significance was determined by a two-way ANOVA with Tukey post hoc test for multiple comparisons. *p < 0.5, **p < 0.01, ***p < 1 × 10−4, ****p < 1 × 10−5..
Facs Buffer (Pbs Edta Lonza With 2% Fcs), supplied by Lonza, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/facs+buffer/pmc09818541-110-5-9?v=Lonza
Average 90 stars, based on 1 article reviews
facs buffer (pbs edta lonza with 2% fcs) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
facs buffer  (Corning Life Sciences)
90
Corning Life Sciences facs buffer
LipoTLR + I generate tolDCs that actively uptake antigen in vitro and in vivo. (A) Analysis of LipoTLR + I In Vitro. 100 k BMDCs were treated with free or liposomal formulations of TLR + I, TLR or I and analyzed via flow <t>cytometry</t> for liposomal uptake. Liposomes were synthesized with AF647-OVA for a total of 1 μg of OVA per .1 μM of inhibitor (using loading procedure from Figure S-4). Free inhibitor formulations were treated with equivalent OVA dose. 1 h after second treatment, cells were washed and analyzed via flow for OVA internalization (B) In Vivo Analysis of LipoTLR + I uptake. C57BL/6 mice (4 per group) were injected with either free or Lipo formulations of OVA and combinations of inhibitors to for the following categories (100 μg OVA/mouse, 10 umols inhibitor/mouse, 1 μg FLA/mouse, 10 μg CpG/mouse) [1]: OVA alone (PBS) [2], OVA + TLR agonists (TLR), OVA + TLR agonists + dexsamethasone only (TLR + Dex) or OVA + Inhibitor combination (TLR + I). For Lipo formulations, DiD was added at 0.01% total lipid loading to allow fluorescent analysis. Mice were injected with either Lipo or free combinations i.p. with FLA then CpG formulations on consecutive days. 24 h after final CpG injection, mice were sacrificed, popliteal and inguinal lymph nodes harvested, disassociated and stained for various immune cell markers. Lymph cells were analyzed via spectral flow and DC populations (CD45+, MHCII+, CD11c+, CD19−) analyzed for CD40, (C) CD80 (D) CD86 (E) CD103 (F) PD-L1 (G) PD-L2. (H) Mice treated with liposomes were gated on Liposome+ and PD-L1/2 + cell populations. Error bars indicate ± of SD of each mouse group (N = 4). Significance was determined by a two-way ANOVA with Tukey post hoc test for multiple comparisons. *p < 0.5, **p < 0.01, ***p < 1 × 10−4, ****p < 1 × 10−5..
Facs Buffer, supplied by Corning Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/facs+buffer/pmc05557726-120-4-13?v=Corning+Life+Sciences
Average 90 stars, based on 1 article reviews
facs buffer - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
facs staining buffer  (Becton Dickinson)
90
Becton Dickinson facs staining buffer
LipoTLR + I generate tolDCs that actively uptake antigen in vitro and in vivo. (A) Analysis of LipoTLR + I In Vitro. 100 k BMDCs were treated with free or liposomal formulations of TLR + I, TLR or I and analyzed via flow <t>cytometry</t> for liposomal uptake. Liposomes were synthesized with AF647-OVA for a total of 1 μg of OVA per .1 μM of inhibitor (using loading procedure from Figure S-4). Free inhibitor formulations were treated with equivalent OVA dose. 1 h after second treatment, cells were washed and analyzed via flow for OVA internalization (B) In Vivo Analysis of LipoTLR + I uptake. C57BL/6 mice (4 per group) were injected with either free or Lipo formulations of OVA and combinations of inhibitors to for the following categories (100 μg OVA/mouse, 10 umols inhibitor/mouse, 1 μg FLA/mouse, 10 μg CpG/mouse) [1]: OVA alone (PBS) [2], OVA + TLR agonists (TLR), OVA + TLR agonists + dexsamethasone only (TLR + Dex) or OVA + Inhibitor combination (TLR + I). For Lipo formulations, DiD was added at 0.01% total lipid loading to allow fluorescent analysis. Mice were injected with either Lipo or free combinations i.p. with FLA then CpG formulations on consecutive days. 24 h after final CpG injection, mice were sacrificed, popliteal and inguinal lymph nodes harvested, disassociated and stained for various immune cell markers. Lymph cells were analyzed via spectral flow and DC populations (CD45+, MHCII+, CD11c+, CD19−) analyzed for CD40, (C) CD80 (D) CD86 (E) CD103 (F) PD-L1 (G) PD-L2. (H) Mice treated with liposomes were gated on Liposome+ and PD-L1/2 + cell populations. Error bars indicate ± of SD of each mouse group (N = 4). Significance was determined by a two-way ANOVA with Tukey post hoc test for multiple comparisons. *p < 0.5, **p < 0.01, ***p < 1 × 10−4, ****p < 1 × 10−5..
Facs Staining Buffer, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/facs+buffer/us11612151-1728-9-7?v=Becton+Dickinson
Average 90 stars, based on 1 article reviews
facs staining buffer - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
facs buffer (1× pbs, 2 mm edta, 0.5% bsa (serva))  (SERVA Electrophoresis)
90
SERVA Electrophoresis facs buffer (1× pbs, 2 mm edta, 0.5% bsa (serva))
LipoTLR + I generate tolDCs that actively uptake antigen in vitro and in vivo. (A) Analysis of LipoTLR + I In Vitro. 100 k BMDCs were treated with free or liposomal formulations of TLR + I, TLR or I and analyzed via flow <t>cytometry</t> for liposomal uptake. Liposomes were synthesized with AF647-OVA for a total of 1 μg of OVA per .1 μM of inhibitor (using loading procedure from Figure S-4). Free inhibitor formulations were treated with equivalent OVA dose. 1 h after second treatment, cells were washed and analyzed via flow for OVA internalization (B) In Vivo Analysis of LipoTLR + I uptake. C57BL/6 mice (4 per group) were injected with either free or Lipo formulations of OVA and combinations of inhibitors to for the following categories (100 μg OVA/mouse, 10 umols inhibitor/mouse, 1 μg FLA/mouse, 10 μg CpG/mouse) [1]: OVA alone (PBS) [2], OVA + TLR agonists (TLR), OVA + TLR agonists + dexsamethasone only (TLR + Dex) or OVA + Inhibitor combination (TLR + I). For Lipo formulations, DiD was added at 0.01% total lipid loading to allow fluorescent analysis. Mice were injected with either Lipo or free combinations i.p. with FLA then CpG formulations on consecutive days. 24 h after final CpG injection, mice were sacrificed, popliteal and inguinal lymph nodes harvested, disassociated and stained for various immune cell markers. Lymph cells were analyzed via spectral flow and DC populations (CD45+, MHCII+, CD11c+, CD19−) analyzed for CD40, (C) CD80 (D) CD86 (E) CD103 (F) PD-L1 (G) PD-L2. (H) Mice treated with liposomes were gated on Liposome+ and PD-L1/2 + cell populations. Error bars indicate ± of SD of each mouse group (N = 4). Significance was determined by a two-way ANOVA with Tukey post hoc test for multiple comparisons. *p < 0.5, **p < 0.01, ***p < 1 × 10−4, ****p < 1 × 10−5..
Facs Buffer (1× Pbs, 2 Mm Edta, 0.5% Bsa (Serva)), supplied by SERVA Electrophoresis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/facs+buffer/pmc11147775-257-3-12?v=SERVA+Electrophoresis
Average 90 stars, based on 1 article reviews
facs buffer (1× pbs, 2 mm edta, 0.5% bsa (serva)) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier
cold facs buffer containing dapi  (Becton Dickinson)
90
Becton Dickinson cold facs buffer containing dapi
LipoTLR + I generate tolDCs that actively uptake antigen in vitro and in vivo. (A) Analysis of LipoTLR + I In Vitro. 100 k BMDCs were treated with free or liposomal formulations of TLR + I, TLR or I and analyzed via flow <t>cytometry</t> for liposomal uptake. Liposomes were synthesized with AF647-OVA for a total of 1 μg of OVA per .1 μM of inhibitor (using loading procedure from Figure S-4). Free inhibitor formulations were treated with equivalent OVA dose. 1 h after second treatment, cells were washed and analyzed via flow for OVA internalization (B) In Vivo Analysis of LipoTLR + I uptake. C57BL/6 mice (4 per group) were injected with either free or Lipo formulations of OVA and combinations of inhibitors to for the following categories (100 μg OVA/mouse, 10 umols inhibitor/mouse, 1 μg FLA/mouse, 10 μg CpG/mouse) [1]: OVA alone (PBS) [2], OVA + TLR agonists (TLR), OVA + TLR agonists + dexsamethasone only (TLR + Dex) or OVA + Inhibitor combination (TLR + I). For Lipo formulations, DiD was added at 0.01% total lipid loading to allow fluorescent analysis. Mice were injected with either Lipo or free combinations i.p. with FLA then CpG formulations on consecutive days. 24 h after final CpG injection, mice were sacrificed, popliteal and inguinal lymph nodes harvested, disassociated and stained for various immune cell markers. Lymph cells were analyzed via spectral flow and DC populations (CD45+, MHCII+, CD11c+, CD19−) analyzed for CD40, (C) CD80 (D) CD86 (E) CD103 (F) PD-L1 (G) PD-L2. (H) Mice treated with liposomes were gated on Liposome+ and PD-L1/2 + cell populations. Error bars indicate ± of SD of each mouse group (N = 4). Significance was determined by a two-way ANOVA with Tukey post hoc test for multiple comparisons. *p < 0.5, **p < 0.01, ***p < 1 × 10−4, ****p < 1 × 10−5..
Cold Facs Buffer Containing Dapi, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/facs+buffer/bio_rxiv__2021__04__28__441728-185-11-21?v=Becton+Dickinson
Average 90 stars, based on 1 article reviews
cold facs buffer containing dapi - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


LipoTLR + I generate tolDCs that actively uptake antigen in vitro and in vivo. (A) Analysis of LipoTLR + I In Vitro. 100 k BMDCs were treated with free or liposomal formulations of TLR + I, TLR or I and analyzed via flow cytometry for liposomal uptake. Liposomes were synthesized with AF647-OVA for a total of 1 μg of OVA per .1 μM of inhibitor (using loading procedure from Figure S-4). Free inhibitor formulations were treated with equivalent OVA dose. 1 h after second treatment, cells were washed and analyzed via flow for OVA internalization (B) In Vivo Analysis of LipoTLR + I uptake. C57BL/6 mice (4 per group) were injected with either free or Lipo formulations of OVA and combinations of inhibitors to for the following categories (100 μg OVA/mouse, 10 umols inhibitor/mouse, 1 μg FLA/mouse, 10 μg CpG/mouse) [1]: OVA alone (PBS) [2], OVA + TLR agonists (TLR), OVA + TLR agonists + dexsamethasone only (TLR + Dex) or OVA + Inhibitor combination (TLR + I). For Lipo formulations, DiD was added at 0.01% total lipid loading to allow fluorescent analysis. Mice were injected with either Lipo or free combinations i.p. with FLA then CpG formulations on consecutive days. 24 h after final CpG injection, mice were sacrificed, popliteal and inguinal lymph nodes harvested, disassociated and stained for various immune cell markers. Lymph cells were analyzed via spectral flow and DC populations (CD45+, MHCII+, CD11c+, CD19−) analyzed for CD40, (C) CD80 (D) CD86 (E) CD103 (F) PD-L1 (G) PD-L2. (H) Mice treated with liposomes were gated on Liposome+ and PD-L1/2 + cell populations. Error bars indicate ± of SD of each mouse group (N = 4). Significance was determined by a two-way ANOVA with Tukey post hoc test for multiple comparisons. *p < 0.5, **p < 0.01, ***p < 1 × 10−4, ****p < 1 × 10−5..

Journal: Biomaterials

Article Title: Robust tolerogenic dendritic cells via push/pull pairing of toll-like-receptor agonists and immunomodulators reduces EAE

doi: 10.1016/j.biomaterials.2022.121571

Figure Lengend Snippet: LipoTLR + I generate tolDCs that actively uptake antigen in vitro and in vivo. (A) Analysis of LipoTLR + I In Vitro. 100 k BMDCs were treated with free or liposomal formulations of TLR + I, TLR or I and analyzed via flow cytometry for liposomal uptake. Liposomes were synthesized with AF647-OVA for a total of 1 μg of OVA per .1 μM of inhibitor (using loading procedure from Figure S-4). Free inhibitor formulations were treated with equivalent OVA dose. 1 h after second treatment, cells were washed and analyzed via flow for OVA internalization (B) In Vivo Analysis of LipoTLR + I uptake. C57BL/6 mice (4 per group) were injected with either free or Lipo formulations of OVA and combinations of inhibitors to for the following categories (100 μg OVA/mouse, 10 umols inhibitor/mouse, 1 μg FLA/mouse, 10 μg CpG/mouse) [1]: OVA alone (PBS) [2], OVA + TLR agonists (TLR), OVA + TLR agonists + dexsamethasone only (TLR + Dex) or OVA + Inhibitor combination (TLR + I). For Lipo formulations, DiD was added at 0.01% total lipid loading to allow fluorescent analysis. Mice were injected with either Lipo or free combinations i.p. with FLA then CpG formulations on consecutive days. 24 h after final CpG injection, mice were sacrificed, popliteal and inguinal lymph nodes harvested, disassociated and stained for various immune cell markers. Lymph cells were analyzed via spectral flow and DC populations (CD45+, MHCII+, CD11c+, CD19−) analyzed for CD40, (C) CD80 (D) CD86 (E) CD103 (F) PD-L1 (G) PD-L2. (H) Mice treated with liposomes were gated on Liposome+ and PD-L1/2 + cell populations. Error bars indicate ± of SD of each mouse group (N = 4). Significance was determined by a two-way ANOVA with Tukey post hoc test for multiple comparisons. *p < 0.5, **p < 0.01, ***p < 1 × 10−4, ****p < 1 × 10−5..

Article Snippet: Splenocytes were then washed using flow cytometry buffer (Stem Cell Technologies), stained for live/dead (Live Dead Aqua) for 30 min, washed and stained for various cell surface markers for 1 h. Cells were washed and analyzed using an Aurora Spectral Flow Cytometer.

Techniques: In Vitro, In Vivo, Flow Cytometry, Synthesized, Injection, Staining